Genentech weighs slow-walking ovarian cancer therapy to make more money under drug pricing reform
Genentech weighs slow-walking ovarian cancer therapy to make more money under drug pricing reform
www.statnews.com Genentech weighs slow-walking ovarian cancer therapy to make more money under drug pricing reform
Plenty of pharma execs have decried Democrats’ new drug pricing law. But few are willing to say they might delay treatments for cancer patients if it means making more money.
Plenty of pharma execs have decried Democrats’ new drug pricing law. But few are willing to say they might delay treatments for cancer patients if it means making more money.
1
comments
Oh please. Putting research/production focus on whatever drugs will make the biggest profit has always been the M.O.